WO2020192606A1 - Kdm5a基因和atrx基因的应用 - Google Patents

Kdm5a基因和atrx基因的应用 Download PDF

Info

Publication number
WO2020192606A1
WO2020192606A1 PCT/CN2020/080579 CN2020080579W WO2020192606A1 WO 2020192606 A1 WO2020192606 A1 WO 2020192606A1 CN 2020080579 W CN2020080579 W CN 2020080579W WO 2020192606 A1 WO2020192606 A1 WO 2020192606A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
cioroni
kdm5a
atrx
efficacy
Prior art date
Application number
PCT/CN2020/080579
Other languages
English (en)
French (fr)
Inventor
鲁先平
山松
潘德思
宁志强
Original Assignee
深圳微芯生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳微芯生物科技股份有限公司 filed Critical 深圳微芯生物科技股份有限公司
Priority to KR1020217034496A priority Critical patent/KR20210143866A/ko
Priority to MX2021011677A priority patent/MX2021011677A/es
Priority to BR112021019155A priority patent/BR112021019155A2/pt
Priority to AU2020246335A priority patent/AU2020246335A1/en
Priority to US17/442,886 priority patent/US20220184056A1/en
Priority to CA3134620A priority patent/CA3134620A1/en
Priority to JP2021557124A priority patent/JP2022527895A/ja
Priority to EP20777844.0A priority patent/EP3950961A4/en
Publication of WO2020192606A1 publication Critical patent/WO2020192606A1/zh
Priority to ZA2021/08165A priority patent/ZA202108165B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present invention relates to the field of medicine technology, in particular to the application of KDM5A gene and ATRX gene.
  • SCLC Small cell lung cancer
  • Untreated patients often die within 2 to 4 months. Although newly-treated patients are more sensitive to chemotherapy, they are prone to drug resistance and relapse, and are relatively insensitive to second-line chemotherapy drugs, and the prognosis is poor. 30% to 40% of the patients diagnosed are in the limited stage, and 60% to 70% of the patients are in the extensive stage. The limited long-term survival rate is 20%, and the extensive period is 2%.
  • Etoposide/cisplatin (EP) regimen is currently the main chemotherapy regimen for SCLC.
  • Phase III clinical study results show that in patients with limited-stage SCLC, the 2-year and 5-year survival rates of EP regimen are better than cyclophosphamide/epirubin Vincristine regimen (25% to 10%, 8% to 3%); for patients with extensive-stage SCLC, the EP regimen can also bring survival benefits.
  • a series of follow-up studies also confirmed the effectiveness of the EP regimen, so the EP regimen has become the standard first-line chemotherapy for SCLC.
  • the purpose of the present invention is to provide the application of KDM5A gene and/or ATRX gene as biomarkers in evaluating the efficacy of Cioroni or guiding Cioroni's medication.
  • Cioroni in Chinese is currently in clinical trials, and its chemical name is N-(2-aminophenyl)-6-(7-methoxyquinoline-4-oxo)-1-naphthamide , Its structural formula is shown in formula (I):
  • the present invention uses Cioroni capsules to conduct a phase Ib clinical trial for relapsed and refractory small cell lung cancer.
  • ctDNA plasma free tumor DNA
  • 548 tumor-related genes have been studied with curative effect-related biomarkers.
  • All patients took blood samples before enrollment, and tested the gene sequence of tumor-related genes, including gene mutations and copy number abnormalities.
  • the test results selected all genes with a mutation rate of more than 0.4%.
  • the patient s progression-free survival (PFS) and objective response rate (ORR) were used as efficacy indicators to analyze the correlation between tumor-related gene abnormalities and the efficacy of Cioroni.
  • PFS progression-free survival
  • ORR objective response rate
  • the present invention also correspondingly proposes the application of products for detecting mutations in the KDM5A gene and/or ATRX gene in the preparation of products for evaluating the curative effect of Cioroni or guiding the medication of Cioroni; and KDM5A gene and/or ATRX The application of genes in the preparation of biomarkers for evaluating the efficacy of Cioroni or guiding Cioroni's medication.
  • the present invention also provides a method for evaluating the efficacy of Cioroni or instructing Cioroni to use drugs, to detect gene mutations in small cell lung cancer tumor tissues. If there is a genetic mutation in the KDM5A gene or the ATRX gene, then Cioroni Nitra has better curative effect.
  • the ctDNA of small cell lung cancer tumor tissue is used as the test sample, and the second-generation sequencing technology is used for detection; there are many methods for detecting gene mutations, which are not limited to the second-generation sequencing technology detection of ctDNA in the specific implementation.
  • gene sequencing for tumor tissues, tumor circulating cells or samples from other human sources, gene sequencing, PCR, FISH, immunohistochemistry and other detection methods can be used to detect gene mutations.
  • the present invention verifies the correlation between the KDM5A gene and ATRX gene mutations and the curative effect of Sioroni by taking the patient’s progression-free survival (PFS) and objective response rate (ORR) as curative effects.
  • PFS progression-free survival
  • ORR objective response rate
  • the detection of gene and ATRX gene mutation information can guide Cioroni's clinical medication and evaluate its curative effect on small cell lung cancer, especially suitable for refractory and relapsed small cell lung cancer.
  • the invention discloses the application of the KDM5A gene and the ATRX gene, and those skilled in the art can learn from the content of this article and appropriately improve the process parameters.
  • all similar substitutions and modifications are obvious to those skilled in the art, and they are all deemed to be included in the present invention.
  • the application of the present invention has been described through the preferred embodiments. It is obvious that relevant personnel can make changes or appropriate changes and combinations to the applications described herein without departing from the content, spirit and scope of the present invention to realize and apply the technology of the present invention .
  • Example 1 Phase Ib clinical trial of Cioroni single-drug treatment of relapsed and refractory small cell lung cancer
  • Test drug Cioroni capsules, specifications: 5mg, 25mg. It is produced by Shenzhen Microchip Biotechnology Co., Ltd.
  • Cioroni capsules are administered at 50 mg/day, QD (no adjustments to body weight or body surface area). Take it on an empty stomach every morning, take it with water, and swallow whole capsules. Continuous administration for 28 days constitutes a treatment cycle, and there is no interval between each treatment cycle.
  • the lesion for radiotherapy or local area treatment must have imaging evidence of disease progression before it can be regarded as a target lesion;
  • Blood biochemistry total bilirubin ⁇ 1.5 times the upper limit of normal, AST/ALT ⁇ 2.5 times the upper limit of normal (if liver metastasis, ⁇ 5 times the upper limit of normal), serum creatinine ⁇ 1.5 times the upper limit of normal;
  • Coagulation function Prothrombin time-international normalized ratio (PT-INR) ⁇ 1.5.
  • test subjects took 50 mg of Cioroni capsules orally once a day, every 28 days as a treatment cycle, and there was no stopping interval during the treatment week. Throughout the trial period, all subjects continued treatment until any of the following conditions (whichever occurs first) occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss to follow-up.
  • Efficacy evaluation According to the RECIST1.1 standard, it will be evaluated once in the baseline period and the 4th weekend after treatment, and repeated every 8 weeks until the disease progresses.
  • Tumor imaging examinations include CT or MRI of the neck, chest, whole abdomen, and pelvis. Examinations of other parts are carried out when necessary based on clinical indications.
  • the baseline and follow-up assessment and measurement of the lesion should use the same techniques and methods.
  • Safety assessment including physical examination, vital signs, ECOG fitness score, blood routine, urine routine, 12-lead ECG, blood biochemistry, electrolytes, coagulation function, myocardial enzymes, troponin, TSH, FT3, FT4, amylase, Echocardiography, 24-hour urine protein quantification (if necessary), adverse events.
  • test results include genetic mutations and copy number abnormalities, as well as analysis of tumor mutational burden (TMB).
  • the plasma free tumor DNA (ctDNA) of the evaluated patients was detected and analyzed, and 548 tumor-related genes were accompanied by the study of efficacy-related biomarkers.
  • the test results selected all genes with a mutation rate of more than 0.4%.
  • the patient’s progression-free survival (PFS) and objective remission (PR) were used as efficacy indicators to analyze the correlation between tumor-related gene abnormalities and the efficacy of Cioroni.
  • the results showed that among the 548 tumor-related genes, only the KDM5A gene and ATRX gene were significantly related to the efficacy of Cioroni.
  • ATRX gene is significantly correlated with the patient's objective remission (PR) benefit.
  • PR objective remission

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供KDM5A基因和/或ATRX基因作为生物标志物在评价西奥罗尼疗效或指导西奥罗尼用药中的应用，以及西奥罗尼在制备用于治疗KDM5A基因或ATRX基因存在基因突变的小细胞肺癌患者的药物中的用途。

Description

KDM5A基因和ATRX基因的应用
本申请要求于2019年3月25日提交中国专利局、申请号为201910228411.9、发明名称为“KDM5A基因和ATRX基因的应用”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
技术领域
本发明涉及药物技术领域，具体涉及KDM5A基因和ATRX基因的应用。
背景技术
肺癌发病率及死亡率均高居恶性肿瘤第一位，小细胞肺癌(small cell lung cancer，SCLC)占肺癌总数的10％～15％，其临床特点和生物学行为异于其他类型肺癌，表现为倍增时间短，早期易发生转移，恶性程度极高。未接受治疗的患者常在2～4个月内死亡，尽管初治患者对化疗较敏感，但很容易产生耐药性和复发，且对二线化疗药物相对不敏感，预后较差。确诊30％～40％的患者处于局限期，60％～70％的患者处于广泛期。局限期长期生存率在20％，广泛期则在2％。
依托泊苷/顺铂(EP)方案是目前SCLC主要化疗方案，III期临床研究结果显示，在局限期SCLC患者中，EP方案的2年和5年生存率优于环磷酰胺/表阿霉素/长春新碱方案(25％比10％，8％比3％)；对于广泛期SCLC患者，EP方案同样可以带来生存获益。后续的一系列研究亦证实了EP方案的有效性，因此EP方案成为SCLC的标准一线化疗。
伊立替康/顺铂(CPT-11/DDP，IP)方案组和EP方案组，结果显示，两组患者的客观缓解率(ORR)分别为84.4％、67.5％(P＝0.02)，中位生存期分别为12.8个月、9.4个月(P＝0.002)。拓扑替康联合最佳支持治疗组总生存期、生活质量及症状的改善均明显优于单用最佳支持治疗组，拓扑替康也成为SCLC的二线化疗药物。总体而言，SCLC缺乏有效的治疗手段，在常规EP或IP方案失败后，二线可选方案较少(如拓扑替康、紫杉醇等)，且二线治疗失败后，NCCN等指南只推荐支持治疗或临床研 究。因此小细胞肺癌，需要探寻更高疗效的治疗方案。
发明内容
有鉴于此，本发明的目的在于提供KDM5A基因和/或ATRX基因作为生物标志物在评价西奥罗尼疗效或指导西奥罗尼用药中的应用。
中文通用名为西奥罗尼的化合物目前处于临床试验阶段，其化学名为N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘酰胺，其结构式如式(I)所示：
Figure PCTCN2020080579-appb-000001
本发明以西奥罗尼胶囊针对复发难治的小细胞肺癌进行Ib期临床试验，通过对血浆游离肿瘤DNA(ctDNA)的检测分析，对548个肿瘤相关基因进行了疗效相关生物标志物的伴随研究。所有患者在入组前均提取血液样品，对肿瘤相关基因的基因序列检测，包括基因突变和拷贝数异常。检测结果选取了所有突变发生率0.4％以上的基因，以患者的无进展生存期(PFS)和客观缓解率(ORR)作为疗效指标，分析肿瘤相关基因异常与西奥罗尼疗效的关联性。结果显示，在548个肿瘤相关基因中，只有KDM5A基因和ATRX基因与西奥罗尼疗效有显著的关联性。
具体试验结果表明，KDM5A基因和ATRX基因的变异分别与西奥罗尼在小细胞肺癌患者中的PFS和ORR存在显著相关性。其中，中位PFS在KDM5A基因突变患者中为145天，野生型患者中为27.5天，P值为0.0087；在以客观缓解(PR)和非缓解(SD+PD)作为疗效评价指标时，ATRX基因突变患者的疗效评价显著优于野生型患者，P值为0.0031。
根据上述技术效果，本发明还对应提出了检测KDM5A基因和/或ATRX基因变异的产品在制备评价西奥罗尼疗效或指导西奥罗尼用药的 产品中的应用；以及KDM5A基因和/或ATRX基因在制备评价西奥罗尼疗效或指导西奥罗尼用药的生物标志物中的应用。
此外，本发明还提供一种评价西奥罗尼疗效或指导西奥罗尼用药的方法，对小细胞肺癌肿瘤组织进行基因突变的检测，若KDM5A基因或ATRX基因存在基因突变，则西奥罗尼的疗效较佳。
在本发明具体实施方式中，以小细胞肺癌肿瘤组织ctDNA为检测样品，采用二代测序技术检测；基因突变的检测手段有多种，并不局限于具体实施中对ctDNA的二代测序技术检测，对肿瘤组织、肿瘤循环细胞或人体其它来源的样品，采用基因测序、PCR、FISH、免疫组化等其它检测手段，均可实现对基因突变的检测。
由以上技术方案可知，本发明通过以患者的无进展生存期(PFS)和客观缓解率(ORR)作为疗效指标，验证了KDM5A基因和ATRX基因变异与西奥罗尼疗效的关联性，对KDM5A基因和ATRX基因突变信息的检测，可以指导西奥罗尼的临床用药和评价其对小细胞肺癌的疗效，特别适用于难治、复发的小细胞肺癌。
具体实施方式
本发明公开了KDM5A基因和ATRX基因的应用，本领域技术人员可以借鉴本文内容，适当改进工艺参数实现。特别需要指出的是，所有类似的替换和改动对本领域技术人员来说是显而易见的，它们都被视为包括在本发明。本发明所述应用已经通过较佳实施例进行了描述，相关人员明显能在不脱离本发明内容、精神和范围内对本文所述应用进行改动或适当变更与组合，来实现和应用本发明技术。
以下就本发明所提供的KDM5A基因和ATRX基因的应用做进一步说明。
实施例1：西奥罗尼单药治疗复发难治的小细胞肺癌的Ib期临床试验
试验药物：西奥罗尼胶囊，规格：5mg、25mg。由深圳微芯生物科 技股份有限公司生产。
给药方案：西奥罗尼胶囊按50mg/天、QD给药(对体重或体表面积不做调整)。每天上午空腹服用，用水送服，完整吞服整粒胶囊。连续给药28天为1个治疗周期，每个治疗周期间无间隔。
病例数：入组25例。
入选标准：
1、年龄≥18岁，≤75岁，性别不限；
2、组织学或细胞学证实的小细胞肺癌；
3、既往至少接受过2种不同的系统化疗方案(其中包括含铂化疗方案)后均出现疾病进展或复发；
4、根据RECIST1.1标准，至少有一个可测量的靶病灶，放疗或局部区域治疗的病灶必须有疾病进展的影像学证据方可视为靶病灶；
5、ECOG体力评分0-1分；
6、主要器官功能符合以下标准：
血常规：中性粒细胞绝对值≥1.5×109/L，血小板≥75×109/L，血红蛋白≥80g/L；
血生化：总胆红素≤正常值上限的1.5倍，AST/ALT≤正常值上限的2.5倍(若肝转移，则≤正常值上限的5倍)，血清肌酐≤正常值上限的1.5倍；
凝血功能：凝血酶原时间-国际标准化比率(PT-INR)<1.5。
7、预期生存时间≥3个月；
8、自愿签署书面知情同意书。
治疗计划：
试验受试者每天口服西奥罗尼胶囊50mg一次，每28天为一个治疗周期，治疗周期间无停药间隔期。整个试验期间，所有受试者均持续治疗直至出现以下任一情况(以先发生者为准)：疾病进展、不能耐受的毒性反应、死亡、撤回知情同意或失访。
疗效评估：根据RECIST1.1标准，分别在基线期以及治疗后第4周末评估一次，后续每8周重复进行，直到疾病进展。肿瘤影像学检查包括颈部、胸部、全腹、盆腔CT或MRI，其他部位检查根据临床指征，有需要时进行，病灶基线和后续评估测量应采用同样的技术和方法。
安全性评估：包括体格检查、生命体征、ECOG体能评分、血常规、尿常规、12导联ECG、血生化、电解质、凝血功能、心肌酶、肌钙蛋白、TSH、FT3、FT4、淀粉酶、超声心动图、24小时尿蛋白定量(必要时)、不良事件。
生物标志物研究：
在受试者首次服用西奥罗尼前和疾病进展时取外周血10毫升，对血浆游离肿瘤DNA(ctDNA)和白细胞提取DNA(对照)进行基因序列的检测，共包括548个肿瘤相关基因，检测结果包括基因突变和拷贝数异常，以及对肿瘤突变负荷(TMB)的分析。
临床试验结果：
入组患者25例，有疗效评价的患者20例，其中有4例患者的最佳疗效评价为部分缓解(PR)，ORR为20％，获益率60％。结果显示西奥罗尼单药治疗小细胞肺癌有效。
对已评价患者血浆游离肿瘤DNA(ctDNA)检测分析，对548个肿瘤相关基因进行了疗效相关生物标志物的伴随研究。检测结果选取了所有突变发生率0.4％以上的基因，以患者的无进展生存期(PFS)和客观缓解(PR)作为疗效指标，分析肿瘤相关基因异常与西奥罗尼疗效的关联性。结果显示，在548个肿瘤相关基因中，只有KDM5A基因和ATRX基因与西奥罗尼疗效有显著的关联性。
KDM5A基因与患者无进展生存期(PFS)获益存在显著相关性，结果见表1。
表1
Figure PCTCN2020080579-appb-000002
表1结果显示，以患者的无进展生存期(PFS)作为疗效评价指标，KDM5A基因突变与患者PFS获益存在显著相关性。KDM5A基因野生型患者共12例，中位PFS为27.5天；KDM5A基因突变型患者共8例，中位PFS为145天。KDM5A基因突变患者和野生型患者无进展生存期存在 显著统计学差异，P值为0.0087。表明KDM5A基因突变型患者在西奥罗尼治疗中能获得更好的获益。
ATRX基因与患者客观缓解(PR)获益存在显著相关性，结果见表2。
表2
Figure PCTCN2020080579-appb-000003
表2结果显示，在以客观缓解(PR)和非缓解(SD+PD)作为疗效评价指标时，ATRX基因突变患者共6例，其中出现客观缓解评价病例4例，占全部突变患者的66.7％，ATRX基因野生型患者共14例，出现客观缓解评价病例0例，占全部野生型患者的0％。ATRX基因突变患者和野生型患者客观缓解情况存在显著统计学差异，P值为0.0031。以上结果表明ATRX基因突变型患者在西奥罗尼治疗中能获得更好的客观缓解获益。
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。

Claims (8)

  1. KDM5A基因和/或ATRX基因作为生物标志物在评价西奥罗尼疗效或指导西奥罗尼用药中的应用。
  2. 检测KDM5A基因和/或ATRX基因变异的产品在制备评价西奥罗尼疗效或指导西奥罗尼用药的产品中的应用。
  3. KDM5A基因和/或ATRX基因在制备评价西奥罗尼疗效或指导西奥罗尼用药的生物标志物中的应用。
  4. 一种评价西奥罗尼疗效或指导西奥罗尼用药的方法，其特征在于，对小细胞肺癌肿瘤组织进行基因突变的检测，若KDM5A基因或ATRX基因存在基因突变，则西奥罗尼的疗效较佳。
  5. 根据权利要求4所述方法，其特征在于，所述检测以ctDNA、肿瘤组织、肿瘤循环细胞或人体其它来源的组织为检测样品。
  6. 根据权利要求4所述方法，其特征在于，所述检测以基因测序、PCR、FISH、免疫组化、ELISA、Western或流式细胞技术为检测方法。
  7. 西奥罗尼在治疗KDM5A基因或ATRX基因存在基因突变的小细胞肺癌患者中的用途。
  8. 西奥罗尼在制备用于治疗KDM5A基因或ATRX基因存在基因突变的小细胞肺癌患者的药物中的用途。
PCT/CN2020/080579 2019-03-25 2020-03-23 Kdm5a基因和atrx基因的应用 WO2020192606A1 (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020217034496A KR20210143866A (ko) 2019-03-25 2020-03-23 Kdm5a 유전자 및 atrx 유전자의 용도
MX2021011677A MX2021011677A (es) 2019-03-25 2020-03-23 Uso del gen kdm5a y del gen atrx.
BR112021019155A BR112021019155A2 (pt) 2019-03-25 2020-03-23 Uso do gene kdm5a e gene atrx
AU2020246335A AU2020246335A1 (en) 2019-03-25 2020-03-23 Application of KDM5A gene and ATRX gene
US17/442,886 US20220184056A1 (en) 2019-03-25 2020-03-23 Use of kdm5a gene and atrx gene
CA3134620A CA3134620A1 (en) 2019-03-25 2020-03-23 Use of kdm5a gene and atrx gene
JP2021557124A JP2022527895A (ja) 2019-03-25 2020-03-23 Ｋｄｍ５ａ遺伝子及びａｔｒｘ遺伝子の使用
EP20777844.0A EP3950961A4 (en) 2019-03-25 2020-03-23 APPLICATION OF A KDM5A GENE AND AN ATRX GENE
ZA2021/08165A ZA202108165B (en) 2019-03-25 2021-10-22 Application of kdm5a gene and atrx gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910228411 2019-03-25
CN201910228411.9 2019-03-25

Publications (1)

Publication Number Publication Date
WO2020192606A1 true WO2020192606A1 (zh) 2020-10-01

Family

ID=72610972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/080579 WO2020192606A1 (zh) 2019-03-25 2020-03-23 Kdm5a基因和atrx基因的应用

Country Status (12)

Country Link
US (1) US20220184056A1 (zh)
EP (1) EP3950961A4 (zh)
JP (1) JP2022527895A (zh)
KR (1) KR20210143866A (zh)
CN (1) CN111733235A (zh)
AU (1) AU2020246335A1 (zh)
BR (1) BR112021019155A2 (zh)
CA (1) CA3134620A1 (zh)
MX (1) MX2021011677A (zh)
TW (1) TWI798532B (zh)
WO (1) WO2020192606A1 (zh)
ZA (1) ZA202108165B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112111577A (zh) * 2020-10-23 2020-12-22 北京诺禾致源科技股份有限公司 基于数字pcr技术的atrx和kdm5a突变检测的试剂盒、装置及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202332445A (zh) * 2019-03-25 2023-08-16 大陸商深圳微芯生物科技股份有限公司 西奧羅尼用於小細胞肺癌的治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105512142A (zh) * 2014-09-26 2016-04-20 深圳华大基因股份有限公司 基因变异与药物关系数据库和数据库系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2887243C (en) * 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
AU2013355260B2 (en) * 2012-12-04 2019-07-25 Caris Mpi, Inc. Molecular profiling for cancer
JP2016520528A (ja) * 2013-03-15 2016-07-14 ジェネンテック， インコーポレイテッド 癌の治療及び抗癌剤耐性の防止方法
EP3265079A4 (en) * 2015-03-03 2019-01-02 Caris MPI, Inc. Molecular profiling for cancer
US20180087114A1 (en) * 2015-03-05 2018-03-29 Trovagene, Inc. Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluid
CN105512412A (zh) * 2015-12-11 2016-04-20 中国北方发动机研究所(天津) 一种增压发动机排气系统匹配优劣的评价方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105512142A (zh) * 2014-09-26 2016-04-20 深圳华大基因股份有限公司 基因变异与药物关系数据库和数据库系统

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SCULIER, ET AL.: "First-and second-line therapy for advanced nonsmall cell lung cancer", EUR. RESPIR. J., vol. 33, no. 11, 1 January 2009 (2009-01-01), pages 915 - 930, XP055588400, DOI: 10.1183/09031936.00132008 *
See also references of EP3950961A4 *
WANG; XINHAO: "Clinical Trials of Etoposide Capsules in Treating Relapsed/Refractory Small Cell Lung Cancer", DRUG CLINICAL TRIAL REGISTRATION AND INFORMATION DISCLOSURE PLATFORM, 27 July 2017 (2017-07-27), pages 1 - 6, XP009526139 *
ZHOU, YOU ET AL.: "CS2164, a Novel Multi-Target Inhibitor against Tumor Angiogenesis, Mitosis and Chronic Inflammation with Anti-tumor Potency", CANCER SCIENCE, vol. 108, no. 3, 31 March 2017 (2017-03-31), XP055737667, DOI: 20200409103527A *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112111577A (zh) * 2020-10-23 2020-12-22 北京诺禾致源科技股份有限公司 基于数字pcr技术的atrx和kdm5a突变检测的试剂盒、装置及应用

Also Published As

Publication number Publication date
CA3134620A1 (en) 2020-10-01
AU2020246335A1 (en) 2021-11-18
BR112021019155A2 (pt) 2022-02-15
KR20210143866A (ko) 2021-11-29
JP2022527895A (ja) 2022-06-07
EP3950961A1 (en) 2022-02-09
TWI798532B (zh) 2023-04-11
MX2021011677A (es) 2021-10-22
US20220184056A1 (en) 2022-06-16
ZA202108165B (en) 2023-06-28
CN111733235A (zh) 2020-10-02
TW202035700A (zh) 2020-10-01
EP3950961A4 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
US20150005264A1 (en) Predictive biomarker for hypoxia-activated prodrug therapy
TWI798532B (zh) Ｋｄｍ５ａ基因和ａｔｒｘ基因的應用
US20140113972A1 (en) Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status
TWI797426B (zh) 西奧羅尼用於小細胞肺癌的治療
Fatima et al. Circulatory proteins in women with breast cancer and their chemotherapeutic responses
Liang et al. A method establishment and comparison of in vivo lung cancer model development platforms for evaluation of tumour metabolism and pharmaceutical efficacy
KR20200015101A (ko) 액체생검 다중 암 유전자 바이오마커를 이용한 유방암 조기진단 및 치료 후 모니터링 방법
Xu et al. Dynamic changes in the body composition during chemotherapy for gastrointestinal tumors in the context of active nutrition intervention
Kapp et al. Synergistic in-vitro effects of combining an antiglycolytic, 3-bromopyruvate, and a bromodomain-4 inhibitor on U937 myeloid leukemia cells
JPWO2007099852A1 (ja) 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット
RU2251692C2 (ru) Способ прогнозирования продолжительности безрецидивного периода у больных раком молочной железы
CN112553342B (zh) 一种肺腺癌诊断的生物标志物及其应用
Groeneweg et al. EP1121 The clinical potential of FOXL2 c. 402C> G mutation detection in circulating tumour DNA of patients with granulosa cell tumours
Johansen et al. A man in his seventies with back pain, gastrointestinal symptoms and rash
Arons et al. Tumor Genomics and the Association with Survival in Recurrent/metastatic Head and Neck Cancer Patients
Ikegame et al. A case of isoniazid-resistant miliary tuberculosis in which tuberculous meningitis paradoxically developed despite systemic improvement
Sharma et al. PHYTONANOMEDICINE: AN INSIGHTS INTO CANCER TREATMENT
Takahashi et al. Efficacy and safety of lenvatinib in 124 Japanese patients with anaplastic thyroid cancer
Russial et al. Clinical Utility of Pre-Treatment and Surveillance Circulating Tumor Tissue Modified Viral HPV DNA to Detect Recurrence in a Community Based HN Cancer Program
Atia 2nd TCMT 2023 Book of Abstracts
Ji A new novel gene ABCC5 promotes castration-resistant prostate cancer progression through ERK carcinogenic pathway
Yu et al. P14. 07 Clinically Predictive Value of Plasma Cell-Free DNA in Lung Cancer Immunotherapy
Jeyaneethi et al. EP1122 Detection of non-haematopoetic circulating cancer-related cells in patients with rare gynaecological cancers
Noguchi et al. A single institute analysis of cell-free DNA concentrations in plasma of patients with various cancer types
Kuligina et al. 1197P Changes in the concentration of EGFR-mutated (EGFR-M+) plasma DNA in the first hours of TKI therapy allow the prediction of tumour response in patients with EGFR-M+ NSCLC

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20777844

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3134620

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021557124

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021019155

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20217034496

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020777844

Country of ref document: EP

Effective date: 20211025

ENP Entry into the national phase

Ref document number: 2020246335

Country of ref document: AU

Date of ref document: 20200323

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112021019155

Country of ref document: BR

Free format text: APRESENTAR, EM ATE 60 (SESSENTA) DIAS, A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO DA PRIORIDADE CN 201910228411.9 DE 25/03/2019 OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTA (NUMERO DE PEDIDO, DATA DO DEPOSITO, PAIS DE ORIGEM, TITULAR E INVENTOR), CONFORME O ART. 15 DA PORTARIA 39/2021, UMA VEZ QUE ESSA INFORMACAO E NECESSARIA PARA O EXAME.

ENP Entry into the national phase

Ref document number: 112021019155

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210924